{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:15:07Z","timestamp":1788945307470,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA231630"],"award-info":[{"award-number":["U54CA231630"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA269272"],"award-info":[{"award-number":["R01CA269272"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["F32CA236183"],"award-info":[{"award-number":["F32CA236183"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA271603"],"award-info":[{"award-number":["R01CA271603"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA231630"],"award-info":[{"award-number":["U54CA231630"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fusion-positive rhabdomyosarcoma (FP-RMS) arises from at least seven distinct oncofusions sharing a common PAX3\/7 N-terminal DNA-binding domain fused to divergent C-terminal partners. How different oncofusions produce the same cancer was unknown. Here we show they are functionally interchangeable, associate with a shared protein network we term the common interactome, bind overlapping target genes, and drive a similar core transcriptional program. The common interactome contains the C-terminal partners of known oncofusions and a newly identified translocation, suggesting oncofusions arise by PAX3\/7 DNA-binding domain fusing to interactome members. As loss of common interactome proteins impaired oncogenic activity we screened the interactome for shared vulnerabilities. This identified thymidylate synthase as preferentially required for FP-RMS growth. Accordingly, the antifolate pralatrexate suppressed growth across all seven oncofusions, in multiple human FP-RMS cell lines, and a patient-derived xenograft. These findings demonstrate that divergent FP-RMS oncofusions are functionally fungible through a shared interactome that defines common vulnerabilities.<\/jats:p>","DOI":"10.1038\/s41467-026-73749-y","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:53:33Z","timestamp":1779965613000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fusion-positive rhabdomyosarcoma oncofusions share a common interactome"],"prefix":"10.1038","volume":"17","author":[{"given":"S. P.","family":"Zimmerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. D.","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. B.","family":"DeGraw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. H.","family":"Rupprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0867-0821","authenticated-orcid":false,"given":"M. J. A.","family":"Groot Koerkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2941-6179","authenticated-orcid":false,"given":"J.","family":"Drost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. A.","family":"Schoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-721X","authenticated-orcid":false,"given":"M. T.","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-7625","authenticated-orcid":false,"given":"J. F.","family":"Shern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. M.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-9940","authenticated-orcid":false,"given":"G. G.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5887-2253","authenticated-orcid":false,"given":"K. C.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Linardic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0748-3079","authenticated-orcid":false,"given":"C. M.","family":"Counter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"73749_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27869","volume":"66","author":"ME Yohe","year":"2019","unstructured":"Yohe, M. E. et al. Insights into pediatric rhabdomyosarcoma research: Challenges and goals. Pediatr. Blood Cancer 66, e27869 (2019).","journal-title":"Pediatr. Blood Cancer"},{"key":"73749_CR2","doi-asserted-by":"publisher","first-page":"e26386","DOI":"10.1002\/pbc.26386","volume":"64","author":"J Selfe","year":"2017","unstructured":"Selfe, J. et al. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials. Pediatr. Blood Cancer 64, e26386 (2017).","journal-title":"Pediatr. Blood Cancer"},{"key":"73749_CR3","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1200\/JCO.2009.26.3814","volume":"28","author":"D Williamson","year":"2010","unstructured":"Williamson, D. et al. Fusion gene\u2013negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J. Clin. Oncol. 28, 2151\u20132158 (2010).","journal-title":"J. Clin. Oncol."},{"key":"73749_CR4","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1158\/0008-5472.CAN-06-3210","volume":"67","author":"CM Linardic","year":"2007","unstructured":"Linardic, C. M. et al. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Res. 67, 6691\u20136699 (2007).","journal-title":"Cancer Res"},{"key":"73749_CR5","doi-asserted-by":"publisher","first-page":"9583","DOI":"10.1158\/0008-5472.CAN-07-6178","volume":"68","author":"S Naini","year":"2008","unstructured":"Naini, S. et al. Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res. 68, 9583\u20139588 (2008).","journal-title":"Cancer Res"},{"key":"73749_CR6","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1101\/gad.1244004","volume":"18","author":"C Keller","year":"2004","unstructured":"Keller, C. et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a\/ARF and Trp53 loss of function. Genes. Dev. 18, 2614\u20132626 (2004).","journal-title":"Genes. Dev."},{"key":"73749_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.bbrc.2007.11.017","volume":"365","author":"K Kikuchi","year":"2008","unstructured":"Kikuchi, K. et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem. Biophys. Res. Commun. 365, 568\u2013574 (2008).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"73749_CR8","doi-asserted-by":"crossref","unstructured":"Ebauer, M., Wachtel, M., Niggli, F. K. & Sch\u00e4fer, B. W. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3\/FKHR. Oncogene\u00a026, 7267\u20137281 (2007).","DOI":"10.1038\/sj.onc.1210525"},{"key":"73749_CR9","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1158\/2159-8290.CD-13-0639","volume":"4","author":"JF Shern","year":"2014","unstructured":"Shern, J. F. et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 4, 216\u2013231 (2014).","journal-title":"Cancer Discov."},{"key":"73749_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/molecules23112798","volume":"23","author":"TH Nguyen","year":"2018","unstructured":"Nguyen, T. H. & Barr, F. G. Therapeutic approaches targeting PAX3-FOXO1 and its regulatory and transcriptional pathways in rhabdomyosarcoma. Molecules 23, 24\u201328 (2018).","journal-title":"Molecules"},{"key":"73749_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101103","volume":"23","author":"BE Gryder","year":"2020","unstructured":"Gryder, B. E. et al. Miswired enhancer logic drives a cancer of the muscle lineage. iScience 23, 101103 (2020).","journal-title":"iScience"},{"key":"73749_CR12","doi-asserted-by":"crossref","unstructured":"Zhang, L. & Wang, C. Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain. Oncogene\u00a026, 1595\u20131605 (2007).","DOI":"10.1038\/sj.onc.1209958"},{"key":"73749_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.cell.2007.05.044","volume":"130","author":"SC Boutet","year":"2007","unstructured":"Boutet, S. C., Disatnik, M.-H., Chan, L. S., Iori, K. & Rando, T. A. Regulation of Pax3 by proteasomal degradation of monoubiquitinated protein in skeletal muscle progenitors. Cell 130, 349\u2013362 (2007).","journal-title":"Cell"},{"key":"73749_CR14","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/sj.onc.1208315","volume":"24","author":"S Begum","year":"2005","unstructured":"Begum, S. et al. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3\/FKHR. Oncogene 24, 1860\u20131872 (2005).","journal-title":"Oncogene"},{"key":"73749_CR15","doi-asserted-by":"publisher","first-page":"6936","DOI":"10.1158\/0008-5472.CAN-05-4578","volume":"66","author":"E Davicioni","year":"2006","unstructured":"Davicioni, E. et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res. 66, 6936\u20136946 (2006).","journal-title":"Cancer Res"},{"key":"73749_CR16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1158\/2159-8290.CD-16-1297","volume":"7","author":"BE Gryder","year":"2017","unstructured":"Gryder, B. E. et al. PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability. Cancer Discov. 7, 884\u2013899 (2017).","journal-title":"Cancer Discov."},{"key":"73749_CR17","first-page":"4704","volume":"62","author":"FG Barr","year":"2002","unstructured":"Barr, F. G. et al. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 62, 4704\u20134710 (2002).","journal-title":"Cancer Res"},{"key":"73749_CR18","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/0008-5472.CAN-04-0844","volume":"64","author":"M Wachtel","year":"2004","unstructured":"Wachtel, M. et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res. 64, 5539\u20135545 (2004).","journal-title":"Cancer Res"},{"key":"73749_CR19","doi-asserted-by":"crossref","unstructured":"Yoshida, H. et al. PAX3-NCOA2 fusion gene has a dual role in promoting the proliferation and inhibiting the myogenic differentiation of rhabdomyosarcoma cells. Oncogene\u00a033, 5601\u20135608 (2014).","DOI":"10.1038\/onc.2013.491"},{"key":"73749_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s00428-023-03501-0","volume":"482","author":"A Meyer","year":"2023","unstructured":"Meyer, A. et al. Biphenotypic sinonasal sarcoma with PAX3::MAML3 fusion transforming into high-grade rhabdomyosarcoma: report of an emerging rare phenomenon. Virchows Arch. 482, 777\u2013782 (2023).","journal-title":"Virchows Arch."},{"key":"73749_CR21","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1038\/sj.onc.1204599","volume":"20","author":"FG Barr","year":"2001","unstructured":"Barr, F. G. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene 20, 5736\u20135746 (2001).","journal-title":"Oncogene"},{"key":"73749_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0959-437X(93)90095-7","volume":"3","author":"M Noll","year":"1993","unstructured":"Noll, M. Evolution and role of Pax genes. Curr. Opin. Genet. Dev. 3, 595\u2013605 (1993).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"73749_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.semcdb.2015.09.011","volume":"44","author":"M Wachtel","year":"2015","unstructured":"Wachtel, M. & Sch\u00e4fer, B. W. Unpeaceful roles of mutant PAX proteins in cancer. Semin. Cell Dev. Biol. 44, 126\u2013134 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"73749_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1101\/gad.301004","volume":"18","author":"F Relaix","year":"2004","unstructured":"Relaix, F., Rocancourt, D., Mansouri, A. & Buckingham, M. Divergent functions of murine Pax3 and Pax7 in limb muscle development. Genes. Dev. 18, 1088\u20131105 (2004).","journal-title":"Genes. Dev."},{"key":"73749_CR25","first-page":"925350","volume":"2014","author":"Y Wang","year":"2014","unstructured":"Wang, Y., Zhou, Y. & Graves, D. T. FOXO transcription factors: their clinical significance and regulation. Biomed. Res. Int. 2014, 925350 (2014).","journal-title":"Biomed. Res. Int."},{"key":"73749_CR26","doi-asserted-by":"crossref","unstructured":"Calnan, D. R. & Brunet, A. The FoxO code. Oncogene\u00a027, 2276\u20132288 (2008).","DOI":"10.1038\/onc.2008.21"},{"key":"73749_CR27","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1210\/me.2003-0116","volume":"17","author":"J Xu","year":"2003","unstructured":"Xu, J. & Li, Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol. Endocrinol. 17, 1681\u20131692 (2003).","journal-title":"Mol. Endocrinol."},{"key":"73749_CR28","doi-asserted-by":"publisher","first-page":"12101","DOI":"10.1074\/jbc.273.20.12101","volume":"273","author":"SA Onate","year":"1998","unstructured":"Onate, S. A. et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 273, 12101\u201312108 (1998).","journal-title":"J. Biol. Chem."},{"key":"73749_CR29","first-page":"287","volume":"159","author":"M Kitagawa","year":"2015","unstructured":"Kitagawa, M. Notch signalling in the nucleus: Roles of Mastermind-like (MAML) transcriptional coactivators. J. Biochem. 159, 287\u2013294 (2015).","journal-title":"J. Biochem."},{"key":"73749_CR30","doi-asserted-by":"publisher","first-page":"41207","DOI":"10.1074\/jbc.M509128200","volume":"280","author":"J Jin","year":"2005","unstructured":"Jin, J. et al. A mammalian chromatin remodeling complex with similarities to the yeast INO80 complex. J. Biol. Chem. 280, 41207\u201341212 (2005).","journal-title":"J. Biol. Chem."},{"key":"73749_CR31","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.1074\/jbc.M111.222505","volume":"286","author":"L Chen","year":"2011","unstructured":"Chen, L. et al. Subunit organization of the human INO80 chromatin remodeling complex: An evolutionarily conserved core complex catalyzes ATP-dependent nucleosome remodeling. J. Biol. Chem. 286, 11283\u201311289 (2011).","journal-title":"J. Biol. Chem."},{"key":"73749_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27176-w","volume":"12","author":"D Laubscher","year":"2021","unstructured":"Laubscher, D. et al. BAF complexes drive proliferation and block myogenic differentiation in fusion-positive rhabdomyosarcoma. Nat. Commun. 12, 6924 (2021).","journal-title":"Nat. Commun."},{"key":"73749_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43780-4","volume":"14","author":"Y Asante","year":"2023","unstructured":"Asante, Y. et al. PAX3-FOXO1 uses its activation domain to recruit CBP\/P300 and shape RNA Pol2 cluster distribution. Nat. Commun. 14, 8361 (2023).","journal-title":"Nat. Commun."},{"key":"73749_CR34","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1016\/j.molcel.2022.10.025","volume":"82","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. PAX3-FOXO1 coordinates enhancer architecture, eRNA transcription, and RNA polymerase pause release at select gene targets. Mol. Cell 82, 4428\u20134442.e7 (2022).","journal-title":"Mol. Cell"},{"key":"73749_CR35","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nbt.4201","volume":"36","author":"TC Branon","year":"2018","unstructured":"Branon, T. C. et al. Efficient proximity labeling in living cells and organisms with TurboID. Nat. Biotechnol. 36, 880\u2013887 (2018).","journal-title":"Nat. Biotechnol."},{"key":"73749_CR36","doi-asserted-by":"crossref","unstructured":"Roux, K. J., Kim, D. I. & Burke, B. BioID: A screen for protein-protein interactions. Curr. Protoc. Protein Sci. 74, 19.23.1\u201319.23.14 (2013).","DOI":"10.1002\/0471140864.ps1923s74"},{"key":"73749_CR37","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1083\/jcb.201112098","volume":"196","author":"KJ Roux","year":"2012","unstructured":"Roux, K. J., Kim, D. I., Raida, M. & Burke, B. A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells. J. Cell Biol. 196, 801\u2013810 (2012).","journal-title":"J. Cell Biol."},{"key":"73749_CR38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176311","volume":"134","author":"RB Day","year":"2023","unstructured":"Day, R. B. et al. Proteogenomic analysis reveals cytoplasmic sequestration of RUNX1 by the acute myeloid leukemia\u2013initiating CBFB::MYH11 oncofusion protein. J. Clin. Invest. 134, e176311 (2023).","journal-title":"J. Clin. Invest."},{"key":"73749_CR39","first-page":"2029","volume":"33","author":"EH Ahn","year":"2013","unstructured":"Ahn, E. H. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Anticancer Res. 33, 2029\u20132035 (2013).","journal-title":"Anticancer Res"},{"key":"73749_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.3978","volume":"30","author":"R Oughtred","year":"2021","unstructured":"Oughtred, R. et al. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 30, 187\u2013200 (2021).","journal-title":"Protein Sci."},{"key":"73749_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","volume":"4","author":"TGP Gr\u00fcnewald","year":"2018","unstructured":"Gr\u00fcnewald, T. G. P. et al. Ewing sarcoma. Nat. Rev. Dis. Prim. 4, 5 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"73749_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejca.2022.05.036","volume":"172","author":"S Hettmer","year":"2022","unstructured":"Hettmer, S. et al. Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children\u2019s Oncology Group and Cooperative Weichteilsarkom-Studiengruppe. Eur. J. Cancer 172, 367\u2013386 (2022).","journal-title":"Eur. J. Cancer"},{"key":"73749_CR43","doi-asserted-by":"publisher","first-page":"6587","DOI":"10.1158\/0008-5472.CAN-08-0859","volume":"68","author":"YX Ren","year":"2008","unstructured":"Ren, Y. X. et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res. 68, 6587\u20136597 (2008).","journal-title":"Cancer Res"},{"key":"73749_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"73749_CR45","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1038\/s41596-020-0373-x","volume":"15","author":"HS Kaya-Okur","year":"2020","unstructured":"Kaya-Okur, H. S., Janssens, D. H., Henikoff, J. G., Ahmad, K. & Henikoff, S. Efficient low-cost chromatin profiling with CUT&Tag. Nat. Protoc. 15, 3264\u20133283 (2020).","journal-title":"Nat. Protoc."},{"key":"73749_CR46","doi-asserted-by":"publisher","first-page":"e19214","DOI":"10.7554\/eLife.19214","volume":"6","author":"IM Tenente","year":"2017","unstructured":"Tenente, I. M. et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife 6, e19214 (2017).","journal-title":"Elife"},{"key":"73749_CR47","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1021\/acs.jproteome.8b00702","volume":"18","author":"NT Doncheva","year":"2019","unstructured":"Doncheva, N. T., Morris, J. H., Gorodkin, J. & Jensen, L. J. Cytoscape StringApp: Network analysis and visualization of proteomics data. J. Proteome Res. 18, 623\u2013632 (2019).","journal-title":"J. Proteome Res."},{"key":"73749_CR48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature11742","volume":"493","author":"Q Chen","year":"2013","unstructured":"Chen, Q., Chen, Y., Bian, C., Fujiki, R. & Yu, X. TET2 promotes histone O-GlcNAcylation during gene transcription. Nature 493, 561\u2013564 (2013).","journal-title":"Nature"},{"key":"73749_CR49","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00504","volume":"6","author":"JY Hehir-Kwa","year":"2022","unstructured":"Hehir-Kwa, J. Y. et al. Improved gene fusion detection in childhood cancer diagnostics using RNA sequencing. JCO Precis. Oncol. 6, e2000504 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"73749_CR50","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1158\/1078-0432.CCR-17-1207","volume":"24","author":"MD Deel","year":"2018","unstructured":"Deel, M. D. et al. The transcriptional coactivator TAZ is a potent mediator of alveolar rhabdomyosarcoma tumorigenesis. Clin. Cancer Res. 24, 2616\u20132630 (2018).","journal-title":"Clin. Cancer Res."},{"key":"73749_CR51","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1172\/JCI67087","volume":"124","author":"LES Crose","year":"2014","unstructured":"Crose, L. E. S. et al. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression. J. Clin. Invest. 124, 285\u2013296 (2014).","journal-title":"J. Clin. Invest."},{"key":"73749_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202216001","volume":"14","author":"MT Meister","year":"2022","unstructured":"Meister, M. T. et al. Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes. EMBO Mol. Med. 14, 1\u201323 (2022).","journal-title":"EMBO Mol. Med."},{"key":"73749_CR53","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e16 (2017).","journal-title":"Cell"},{"key":"73749_CR54","doi-asserted-by":"crossref","unstructured":"Hwang, S. P. & Denicourt, C. The impact of ribosome biogenesis in cancer: From proliferation to metastasis. NAR Cancer 6, zcae017 (2024).","DOI":"10.1093\/narcan\/zcae017"},{"key":"73749_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32023-7","volume":"13","author":"H Dorado Garc\u00eda","year":"2022","unstructured":"Dorado Garc\u00eda, H. et al. Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. Nat. Commun. 13, 4297 (2022).","journal-title":"Nat. Commun."},{"key":"73749_CR56","unstructured":"Hoffman, R. A. et al. Fusion transcription factor dosage controls cell state in rhabdomyosarcoma. bioRxiv 2025 May 21, 2025.05.16.654522 (2025)."},{"key":"73749_CR57","doi-asserted-by":"publisher","first-page":"105457","DOI":"10.1016\/j.jbc.2023.105457","volume":"299","author":"B Petrova","year":"2023","unstructured":"Petrova, B., Maynard, A. G., Wang, P. & Kanarek, N. Regulatory mechanisms of one-carbon metabolism enzymes. J. Biol. Chem. 299, 105457 (2023).","journal-title":"J. Biol. Chem."},{"key":"73749_CR58","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","volume":"11","author":"PM Wilson","year":"2014","unstructured":"Wilson, P. M., Danenberg, P. V., Johnston, P. G., Lenz, H. J. & Ladner, R. D. Standing the test of time: Targeting thymidylate biosynthesis in cancer therapy. Nat. Rev. Clin. Oncol. 11, 282\u2013298 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73749_CR59","unstructured":"Eli Lilly and Company. ALIMTA (pemetrexed disodium injection) [package insert]. FDA MedWatch (2023)."},{"key":"73749_CR60","unstructured":"Pfizer. Tomudex (raltitrexed for injection) [package insert]. FDA MedWatch (2021)."},{"key":"73749_CR61","unstructured":"West-Ward Pharmaceuticals Corp. Methotrexate tablets [package insert]. FDA MedWatch (2020)."},{"key":"73749_CR62","unstructured":"Spectrum Pharmaceuticals Inc. Fluorouracil injection [package insert]. FDA MedWatch (2016)."},{"key":"73749_CR63","unstructured":"Allos Therapeutics. Folotyn (pralatrexate injection) [package insert]. FDA MedWatch (2009)."},{"key":"73749_CR64","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1054\/bjoc.1999.1030","volume":"82","author":"M Eidi Nita","year":"1998","unstructured":"Eidi Nita, M. et al. 5-Fluorouracil induces apoptosis in human colon cancer cell lines with modulation of Bcl-2 family proteins. Br. J. Cancer 82, 998\u20131005 (1998).","journal-title":"Br. J. Cancer"},{"key":"73749_CR65","doi-asserted-by":"publisher","first-page":"83","DOI":"10.18388\/abp.2010_2376","volume":"57","author":"M Jagiello","year":"2010","unstructured":"Jagiello, M., Kanska, U., Nevozhay, D. & Boratynski, J. Synthesis and biological activity of raltitrexed-carrier conjugates. Acta Biochim. Pol. 57, 83\u201387 (2010).","journal-title":"Acta Biochim. Pol."},{"key":"73749_CR66","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","volume":"16","author":"E Marchi","year":"2010","unstructured":"Marchi, E. et al. Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies. Clin. Cancer Res. 16, 3648\u20133658 (2010).","journal-title":"Clin. Cancer Res."},{"key":"73749_CR67","first-page":"50","volume":"8","author":"AA Ovejera","year":"1978","unstructured":"Ovejera, A. A., Houchens, D. P. & Barker, A. D. Chemotherapy of human tumor xenografts in genetically athymic mice. Ann. Clin. Lab. Sci. 8, 50\u201356 (1978).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"73749_CR68","first-page":"3245","volume":"22","author":"Y Kabeshima","year":"2002","unstructured":"Kabeshima, Y. et al. A potential imortant role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed. Anticancer Res. 22, 3245\u20133252 (2002).","journal-title":"Anticancer Res"},{"key":"73749_CR69","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","volume":"44","author":"ES Wang","year":"2003","unstructured":"Wang, E. S. et al. Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk. Lymphoma 44, 1027\u20131035 (2003).","journal-title":"Leuk. Lymphoma"},{"key":"73749_CR70","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-14-1797","volume":"21","author":"JJG Kephart","year":"2015","unstructured":"Kephart, J. J. G. et al. Secreted frizzled-related protein 3 (SFRP3) is required for tumorigenesis of PAX3-FOXO1-positive alveolar rhabdomyosarcoma. Clin. Cancer Res. 21, 4868\u20134880 (2015).","journal-title":"Clin. Cancer Res."},{"key":"73749_CR71","doi-asserted-by":"publisher","first-page":"457","DOI":"10.18388\/abp.1995_4899","volume":"42","author":"D Banerjee","year":"1995","unstructured":"Banerjee, D. et al. Molecular mechanisms of resistance to antifolates, a review. Acta Biochim. Pol. 42, 457\u2013464 (1995).","journal-title":"Acta Biochim. Pol."},{"key":"73749_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50527-2","volume":"15","author":"SG Danielli","year":"2024","unstructured":"Danielli, S. G. et al. Single cell transcriptomic profiling identifies tumor-acquired and therapy-resistant cell states in pediatric rhabdomyosarcoma. Nat. Commun. 15, 6307 (2024).","journal-title":"Nat. Commun."},{"key":"73749_CR73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature23647","volume":"549","author":"E Stewart","year":"2017","unstructured":"Stewart, E. et al. Orthotopic patient-derived xenografts of paediatric solid tumours. Nature 549, 96\u2013100 (2017).","journal-title":"Nature"},{"key":"73749_CR74","doi-asserted-by":"publisher","first-page":"38022","DOI":"10.18632\/oncotarget.16723","volume":"8","author":"RB Mokhtari","year":"2017","unstructured":"Mokhtari, R. B. et al. Combination therapy in combating cancer. Oncotarget 8, 38022\u201338043 (2017).","journal-title":"Oncotarget"},{"key":"73749_CR75","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski","year":"2024","unstructured":"Roskoski, R. Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update. Pharmacol. Res. 200, 107059 (2024).","journal-title":"Pharmacol. Res."},{"key":"73749_CR76","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"73749_CR77","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4155\/fmc-2020-0240","volume":"13","author":"S Tadesse","year":"2021","unstructured":"Tadesse, S., Duckett, D. R. & Monastyrskyi, A. The promise and current status of CDK12\/13 inhibition for the treatment of cancer. Future Med. Chem. 13, 117\u2013141 (2021).","journal-title":"Future Med. Chem."},{"key":"73749_CR78","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR79","doi-asserted-by":"publisher","first-page":"10222","DOI":"10.1002\/cam4.5749","volume":"12","author":"W Allen-Rhoades","year":"2023","unstructured":"Allen-Rhoades, W. et al. Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed\/refractory disease: A meta-analysis. Cancer Med. 12, 10222\u201310229 (2023).","journal-title":"Cancer Med"},{"key":"73749_CR80","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1002\/cncr.10600","volume":"94","author":"M Casanova","year":"2002","unstructured":"Casanova, M. et al. Vinorelbine in previously treated advanced childhood sarcomas: Evidence of activity in rhadbomyosarcoma. Cancer 94, 3263\u20133268 (2002).","journal-title":"Cancer"},{"key":"73749_CR81","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41594-020-00550-w","volume":"28","author":"S Terlecki-Zaniewicz","year":"2021","unstructured":"Terlecki-Zaniewicz, S. et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat. Struct. Mol. Biol. 28, 190\u2013201 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"73749_CR82","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","volume":"37","author":"C Lin","year":"2010","unstructured":"Lin, C. et al. AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 37, 429\u2013437 (2010).","journal-title":"Mol. Cell"},{"key":"73749_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38886-8","volume":"14","author":"J DeMartino","year":"2023","unstructured":"DeMartino, J. et al. Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma. Nat. Commun. 14, 3074 (2023).","journal-title":"Nat. Commun."},{"key":"73749_CR84","doi-asserted-by":"publisher","first-page":"723","DOI":"10.21873\/cgp.20293","volume":"18","author":"I Panagopoulos","year":"2021","unstructured":"Panagopoulos, I. et al. Fusion of the paired box 3 (PAX3) and myocardin (MYOCD) genes in pediatric rhabdomyosarcoma. Cancer Genom. Proteom. 18, 723\u2013734 (2021).","journal-title":"Cancer Genom. Proteom."},{"key":"73749_CR85","doi-asserted-by":"publisher","first-page":"973723","DOI":"10.1155\/2012\/973723","volume":"2012","author":"AT Mikhailov","year":"2012","unstructured":"Mikhailov, A. T. & Torrado, M. In search of novel targets for heart disease: myocardin and myocardin-related transcriptional cofactors. Biochem. Res. Int. 2012, 973723 (2012).","journal-title":"Biochem. Res. Int."},{"key":"73749_CR86","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0959-437X(02)00358-1","volume":"12","author":"MW Nachman","year":"2002","unstructured":"Nachman, M. W. Variation in recombination rate across the genome: Evidence and implications. Curr. Opin. Genet. Dev. 12, 657\u2013663 (2002).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"73749_CR87","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41379-021-00744-7","volume":"34","author":"YC Kao","year":"2021","unstructured":"Kao, Y. C. et al. Recurrent MEIS1-NCOA2\/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tracts. Mod. Pathol. 34, 1203\u20131212 (2021).","journal-title":"Mod. Pathol."},{"key":"73749_CR88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/PAS.0000000000001153","volume":"43","author":"BC Dickson","year":"2019","unstructured":"Dickson, B. C. et al. Uterine tumor resembling ovarian sex cord tumor: A distinct entity characterized by recurrent NCOA2\/3 gene fusions. Am. J. Surg. Pathol. 43, 178\u2013186 (2019).","journal-title":"Am. J. Surg. Pathol."},{"key":"73749_CR89","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/PAS.0000000000000591","volume":"40","author":"K Specht","year":"2016","unstructured":"Specht, K. et al. Novel BCOR-MAML3 and ZC3H7B-BCOR gene fusions in undifferentiated small blue round cell sarcomas. Am. J. Surg. Pathol. 40, 433\u2013442 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"73749_CR90","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.humpath.2018.08.011","volume":"83","author":"J Guilmette","year":"2019","unstructured":"Guilmette, J., Dias-Santagata, D., Nos\u00e9, V., Lennerz, J. K. & Sadow, P. M. Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family. Hum. Pathol. 83, 50\u201358 (2019).","journal-title":"Hum. Pathol."},{"key":"73749_CR91","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1182\/blood-2009-07-234229","volume":"115","author":"E Coyaud","year":"2010","unstructured":"Coyaud, E. et al. Wide diversity of PAX5 alterations in B-ALL: A Groupe Francophone de Cytog\u00e9n\u00e9tique H\u00e9matologique study. Blood 115, 3089\u20133097 (2010).","journal-title":"Blood"},{"key":"73749_CR92","doi-asserted-by":"crossref","first-page":"D817","DOI":"10.1093\/nar\/gkz1018","volume":"48","author":"YE Jang","year":"2020","unstructured":"Jang, Y. E. et al. ChimerDB 4.0: An updated and expanded database of fusion genes. Nucleic Acids Res. 48, D817\u2013D824 (2020).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR93","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/nar\/gkp982","volume":"38","author":"P Kim","year":"2009","unstructured":"Kim, P. et al. ChimerDB 2.0\u2009A knowledgebase for fusion genes updated. Nucleic Acids Res. 38, 81\u201385 (2009).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR94","doi-asserted-by":"publisher","first-page":"D1221","DOI":"10.1093\/nar\/gkab1056","volume":"50","author":"P Kim","year":"2022","unstructured":"Kim, P. et al. FusionGDB 2.0: Fusion gene annotation updates aided by deep learning. Nucleic Acids Res. 50, D1221\u2013D1230 (2022).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR95","doi-asserted-by":"publisher","first-page":"D994","DOI":"10.1093\/nar\/gky1067","volume":"47","author":"P Kim","year":"2019","unstructured":"Kim, P. & Zhou, X. FusionGDB: Fusion gene annotation DataBase. Nucleic Acids Res 47, D994\u2013D1004 (2019).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41655-2","volume":"14","author":"S Tripathi","year":"2023","unstructured":"Tripathi, S. et al. Defining the condensate landscape of fusion oncoproteins. Nat. Commun. 14, 6008 (2023).","journal-title":"Nat. Commun."},{"key":"73749_CR97","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41573-021-00199-0","volume":"20","author":"MJ Henley","year":"2021","unstructured":"Henley, M. J. & Koehler, A. N. Advances in targeting \u2018undruggable\u2019 transcription factors with small molecules. Nat. Rev. Drug Discov. 20, 669\u2013688 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"73749_CR98","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1158\/0008-5472.CAN-25-0315","volume":"85","author":"KI Paras","year":"2025","unstructured":"Paras, K. I. et al. PAX3-FOXO1 Drives targetable cell state\u2013dependent metabolic vulnerabilities in rhabdomyosarcoma. Cancer Res. 85, 4718\u20134733 (2025).","journal-title":"Cancer Res"},{"key":"73749_CR99","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1038\/s41388-023-02694-7","volume":"42","author":"MV Guijarro","year":"2023","unstructured":"Guijarro, M. V. et al. TYMS promotes genomic instability and tumor progression in Ink4a\/Arf null background. Oncogene 42, 1926\u20131939 (2023).","journal-title":"Oncogene"},{"key":"73749_CR100","doi-asserted-by":"crossref","unstructured":"Krivit, W. & Bentley, H. P. Use of 5-Fluorouracil in the management of advanced malignancies in childhood. Am. J. Dis. Child. 100, 217\u2013227 (1960).","DOI":"10.1001\/archpedi.1960.04020040219010"},{"key":"73749_CR101","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00043426-199709000-00006","volume":"19","author":"AS Pappo","year":"1997","unstructured":"Pappo, A. S. et al. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 19, 438\u2013442 (1997).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"73749_CR102","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1200\/JCO.2011.38.5591","volume":"30","author":"E Missiaglia","year":"2012","unstructured":"Missiaglia, E. et al. PAX3\/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J. Clin. Oncol. 30, 1670\u20131677 (2012).","journal-title":"J. Clin. Oncol."},{"key":"73749_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12896-017-0341-x","volume":"17","author":"SB Frank","year":"2017","unstructured":"Frank, S. B., Schulz, V. V. & Miranti, C. K. A streamlined method for the design and cloning of shRNAs into an optimized Dox-inducible lentiviral vector. BMC Biotechnol. 17, 1\u201310 (2017).","journal-title":"BMC Biotechnol."},{"key":"73749_CR104","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.cell.2021.01.012","volume":"184","author":"RE Hanna","year":"2021","unstructured":"Hanna, R. E. et al. Massively parallel assessment of human variants with base editor screens. Cell 184, 1064\u20131080.e20 (2021).","journal-title":"Cell"},{"key":"73749_CR105","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ydbio.2015.03.001","volume":"411","author":"E Stewart","year":"2016","unstructured":"Stewart, E. et al. The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev. Biol. 411, 287\u2013293 (2016).","journal-title":"Dev. Biol."},{"key":"73749_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson, K. R. et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat. Commun. 9, 5416 (2018).","journal-title":"Nat. Commun."},{"key":"73749_CR107","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2015.02.038","volume":"160","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell 160, 1246\u20131260 (2015).","journal-title":"Cell"},{"key":"73749_CR108","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828\u2013863 (2017).","journal-title":"Nat. Protoc."},{"key":"73749_CR109","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. Fastp: An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"73749_CR110","doi-asserted-by":"publisher","first-page":"D802","DOI":"10.1093\/nar\/gkx1011","volume":"46","author":"PJ Kersey","year":"2018","unstructured":"Kersey, P. J. et al. Ensembl Genomes 2018: An integrated omics infrastructure for non-vertebrate species. Nucleic Acids Res. 46, D802\u2013D808 (2018).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR111","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"73749_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome. Biol. 15, 1\u201321 (2014).","journal-title":"Genome. Biol."},{"key":"73749_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121 (2015).","journal-title":"Nat. Methods"},{"key":"73749_CR114","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nmeth.3885","volume":"13","author":"N Ignatiadis","year":"2016","unstructured":"Ignatiadis, N., Klaus, B., Zaugg, J. B. & Huber, W. Data-driven hypothesis weighting increases detection power in genome-scale multiple testing. Nat. Methods 13, 577\u2013580 (2016).","journal-title":"Nat. Methods"},{"key":"73749_CR115","first-page":"275","volume":"18","author":"M Stephens","year":"2017","unstructured":"Stephens, M. False discovery rates: A new deal. Biostatistics 18, 275\u2013294 (2017).","journal-title":"Biostatistics"},{"key":"73749_CR116","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","volume":"38","author":"S Heinz","year":"2010","unstructured":"Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576\u2013589 (2010).","journal-title":"Mol. Cell"},{"key":"73749_CR117","doi-asserted-by":"publisher","first-page":"W160","DOI":"10.1093\/nar\/gkw257","volume":"44","author":"F Ram\u00edrez","year":"2016","unstructured":"Ram\u00edrez, F. et al. deepTools2: a next generation web server for deep-sequencing data analysis. Nucleic Acids Res 44, W160\u2013W165 (2016).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR118","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.1630","volume":"28","author":"CY McLean","year":"2010","unstructured":"McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495\u2013501 (2010).","journal-title":"Nat. Biotechnol."},{"key":"73749_CR119","doi-asserted-by":"crossref","unstructured":"Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome. Res. 13, 2498\u20132504 (2003).","DOI":"10.1101\/gr.1239303"},{"key":"73749_CR120","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"73749_CR121","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg, L. et al. G:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 51, W207\u2013W212 (2023).","journal-title":"Nucleic Acids Res"},{"key":"73749_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome. Biol. 15, 554 (2014).","journal-title":"Genome. Biol."},{"key":"73749_CR123","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the Cancer Dependency Map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"73749_CR124","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73749-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73749-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:01:50Z","timestamp":1784952110000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73749-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73749"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73749-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M.C. is co-Founder of Merlon Inc, a member of the External Advisory Board for the University of Colorado Cancer Center, has a cross appointment with Duke-NUS, is an ex-officio of the executive team for the Cancer Biology Training Consortium, has previously consulted for the Guidepoint Network in an ad hoc fashion, and received licensing reimbursement from Humacyte Inc. C.M.L. has received research funding from Ryvu, C.M.L.\u2019s spouse is founder of Grid Therapeutics, and C.M.L.\u2019s family has stock in LabCorp, and ThermoFisher. K.C.W. is a founder and equity holder at Tavros Therapeutics, Aurova Therapeutics, and Celldom, a scientific advisor and equity holder at Stelexis Therapeutics and Decrypt Bio, and has performed consulting work for Retroviral Proviromics, Guidepoint Global, Bantam Pharmaceuticals, Quantum SI, and Apple Tree Partners. R.A.S. is principal investigator on two investigator-initiated studies, for which research funding is contributed to the institution for the conduct of the study (Takeda, Pfizer). None of these relationships provided salary or research support, nor did they play a role in the study design, data collection, data analysis, or decision to publish for this project. The remaining authors have no conflicts to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6933"}}